Berubicin hydrochloride is a small molecule commercialized by CNS Pharmaceuticals, with a leading Phase II program in Recurrent Glioblastoma Multiforme (GBM). According to Globaldata, it is involved in 8 clinical trials, of which 1 was completed, 2 are ongoing, 2 are planned, and 3 were terminated. GlobalData uses proprietary data and analytics to provide a complete picture of Berubicin hydrochloride’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.
The revenue for Berubicin hydrochloride is expected to reach an annual total of $19 mn by 2035 in the US based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.
Berubicin hydrochloride Overview
Berubicin hydrochloride (RTA 744) is under development for the treatment of glioblastoma, recurrent glioblastoma multiforme, CNS lymphoma, breast cancer, lung cancer, malignant glioma, pediatric brain tumor, pancreatic cancer, high grade gliomas, ovarian cancer and lymphomas. The drug candidate is an anthracycline derivative. It is a lyophilized drug product administered intravenously. It is a potent inhibitor of topoisomerase II. The drug circumvent ATP-binding cassette transporters(multidrug resistance protein 1, breast cancer resistance protein, P-glycoprotein). It was also under development for the treatment of metastatic breast cancer, brain metastasis, anaplastic astrocytoma, anaplastic mixed oligo-astrocytoma, anaplastic oligodendroglioma, neoplastic meningitis (leptomeningeal carcinomatosis) and malignant glioma.
CNS Pharmaceuticals Overview
CNS Pharmaceuticals is a pre-clinical stage biotechnology company specialized in developing novel medicines for brain tumours. It carries out research and development operation in matters related to various cancer treatments and related drugs. The company offers anticancer drug treatment for brain and central nervous system tumors. CNS Pharmaceuticals product portfolio includes Berubicin and WP1244. The company’s products find application in various therapeutic areas such as treatment for glioblastoma, brain tumor and other related concerns. It is also involved in developing treatment for pancreatic and ovarian cancers. The company has obtained patent from Houston Pharmaceuticals as well as collaborated with Reata Pharmaceuticals for developing its pipeline products. CNS Pharmaceuticals is headquartered in Texas, the US
The operating loss of the company was US$14 million in FY2021, compared to an operating loss of US$9.5 million in FY2020. The net loss of the company was US$14 million in FY2021, compared to a net loss of US$9.5 million in FY2020.
For a complete picture of Berubicin hydrochloride’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.